CAR-T療法の世界市場

◆英語タイトル:MarketVIEW: CAR-T therapies overview
◆商品コード:VACZ712004
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2017年3月
◆ページ数:※お問い合わせください。
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD5,780 ⇒換算¥624,240見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

CAR-T or Chimeric Antigen Receptor T cells are a sub component of Adoptive T Cell therapy (ACT) , a promising new treatment intervention for cancer. In ACT, a patient’s individual T cells are removed and manipulated so they have an increased capacity to fight cancer. The therapy is usually personalized (autologous) for a specific patient.
Chimeric antigen receptor T cells present hybrid receptors consisting of an antigen binding domain of an antibody (e.g. directed to CD19) fused to the T-cell receptor signalling domain. So far, the technology has undergone four generations of development, where second-generation approaches have shown remarkable responses in clinical studies. Complete remission in up to 90% of patients have been reported for relapsed or refractory B-cell Acute Lymphoblastic Leukaemia (B-ALL). Since 2015/2016 commercial interest has heightened in the development of CAR-T therapies with companies such as Novartis, Pfizer (Cellectis), Medimmune, Juno Therapeutics, and Kite Pharma involved in clinical studies, mainly against hematological cancers.

This MarketVIEW product consists of a product consists of a detailed Executive presentation (~91 slides) and MS-Excel work book summarizing latest developments in CAR-T therapies with a full review of the field to date. A searchable database of nearly 200 CAR trials has been compiled with analysis by start date, current phase, indication and sponsor type (industry and/or academic). For the hematological cancers, detailed case studies are provided looking at clinical trial parameters and data presented to date. Future perspectives, key risks, and challenges along with summary and conclusions are provided. This analysis is ideal for those wishing to gain an up-to-date understanding of the CAR-T landscape.

【レポートの目次】

Contents
Executive summary
Chimeric Antigen Receptors (CAR) – Background
Cancer Immunotherapy
Adoptive T cell therapy – T cells
Categories of adoptive T cell therapies
Adoptive T cell therapy – TIL approach
Adoptive T cell therapy – Genetically modified T cell approach
Adoptive T cell therapy – Genetically modified T cell approach – Engineered T cell receptor
Adoptive T cell therapy – Genetically modified T cell approach – Chimeric Antigen Receptor T cells (CAR-T)
Adoptive T cell therapy – Antigen selection for a CAR-T approach
CAR-T cell therapy – Potential issues and challenges
Chimeric Antigen Receptor T cells (CAR-T) – Review of Key Successful Clinical Trials
CAR-T cell therapy – successful clinical trials for CD19-CAR-T targeting acute lymphoblastic leukaemia
CAR-T cell therapy – successful clinical trials for CD19-CAR-T targeting lymphoma
Chimeric Antigen Receptors (CAR) – Current R&D pipeline
CAR-T Therapy – pipeline analysis methodology
Chimeric Antigen Receptor (CAR) Trials: total number of clinical trials
Chimeric Antigen Receptor (CAR) Trials: activity 2008-present
Chimeric Antigen Receptor (CAR) Trials: activity (industry)
Chimeric Antigen Receptor (CAR) Trials: activity (non industry)
Chimeric Antigen Receptor (CAR) Trials: phases and sponsor type
Chimeric Antigen Receptor (CAR) Trials: target indications (all phases)
Chimeric Antigen Receptor (CAR) Trials: phase I-IV, by indication
Chimeric Antigen Receptor (CAR) Trials: haematological indications, phases and sponsor type
Chimeric Antigen Receptor (CAR) Trials: multiple indications – phases and sponsor type
Chimeric Antigen Receptor (CAR) Trials: neurological indications – phases and sponsor type
Chimeric Antigen Receptors (CAR) – Advanced Clinical Trials for Blood Cancer Targets: Leukaemia/Lymphoma/Myeloma
Chimeric Antigen Receptor (CAR) Trials – haematological cancer targets
Blood cancer targets for CAR-T therapy: Leukaemia (background)
Leukaemia: survival rates and treatment types
Blood cancer targets for CAR-T therapy: Lymphoma (background) and survival rates
Lymphoma: current treatments
Blood cancer targets for CAR-T therapy: Myeloma (background), survival rates and current treatments
Advanced Clinical Trials for Leukaemia/Lymphoma/Myeloma
Leukaemia/Lymphoma/Myeloma – Industry sponsored CAR-T studies
Chimeric Antigen Receptors (CAR) – In depth review of key industry sponsored programmes
3 Contents available on request
2 Presentation titles may apply to more than one slide

Bluebird bio, Celgene Corporation: BB2121
Cellular Biomedicine Group Ltd: C-CAR011
Celyad: NKR2
Juno Therapeutics Inc, Celgene Corporation: JCAR017
Juno Therapeutics Inc, Celgene Corporation: other CD19+ trials
Juno Therapeutics Inc: CAR-T trials for additional targets
Juno Therapeutics, Inc., MedImmune LLC: JCAR014
Takara Bio Inc
Kite Pharma: KTE-C19
Novartis: CTL019
Novartis: CD19 CAR-T Long Term Follow Up
Servier, Cellectis, Pfizer: UCART19
Cellectis: additional UCARTS
CAR-T - summary and conclusions
Bibliography
About VacZine Analytics
Disclaimer
Slide number = 99

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ CAR-T療法の世界市場(MarketVIEW: CAR-T therapies overview)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆